{
    "pmcid": "11762740",
    "qa_pairs": {
        "What challenge does the reducing environment of E. coli's cytoplasm pose for nanobody production?": [
            "It disrupts disulfide bonds crucial for nanobody stability",
            "It increases the rate of protein degradation",
            "It enhances the formation of protein aggregates",
            "It reduces the solubility of nanobodies"
        ],
        "What is the primary target for the nanobodies produced in the study using Escherichia coli?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What potential applications are highlighted for the nanobodies produced using the sfGFP-driven secretory expression system?": [
            "Commercial diagnostics, therapeutic agents, and research applications",
            "Vaccine development, antiviral drug formulation, and gene therapy",
            "Environmental monitoring, food safety testing, and agricultural biotechnology",
            "Cancer treatment, autoimmune disease therapy, and metabolic disorder management"
        ],
        "What strategy was employed to facilitate nanobody secretion and expression in Escherichia coli?": [
            "Using super-folder green fluorescent protein (sfGFP) as a fusion partner",
            "Using a heat shock protein as a fusion partner",
            "Using a maltose-binding protein as a fusion partner",
            "Using a thioredoxin tag as a fusion partner"
        ],
        "Which nanobody combination was used to create a bispecific nanobody with enhanced affinity and neutralizing potential?": [
            "Fu2-sfGFP-ANTE",
            "Fu2-mNb6",
            "MR3-MR3-n3113.1",
            "ANTE-mNb6"
        ]
    }
}